AR035982A1 - Derivados de c-furano-2-il-metilamina y c-tiofeno-2-il-metilamina sustituidos y metodo de preparacion - Google Patents
Derivados de c-furano-2-il-metilamina y c-tiofeno-2-il-metilamina sustituidos y metodo de preparacionInfo
- Publication number
- AR035982A1 AR035982A1 ARP020101843A ARP020101843A AR035982A1 AR 035982 A1 AR035982 A1 AR 035982A1 AR P020101843 A ARP020101843 A AR P020101843A AR P020101843 A ARP020101843 A AR P020101843A AR 035982 A1 AR035982 A1 AR 035982A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- heterocyclyl
- cyclopropyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 239000003814 drug Substances 0.000 abstract 6
- 229940079593 drug Drugs 0.000 abstract 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- MWDNKIZPKUIHES-UHFFFAOYSA-N 1,2-bis(furan-2-yl)-2-(pyrazin-2-ylamino)ethanone Chemical compound C=1C=COC=1C(=O)C(C=1OC=CC=1)NC1=CN=CC=N1 MWDNKIZPKUIHES-UHFFFAOYSA-N 0.000 abstract 1
- XKNAGLMNQADBQE-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CN=CC=3)=CC=2)=N1 XKNAGLMNQADBQE-UHFFFAOYSA-N 0.000 abstract 1
- ZOIWPXRLLGGGKK-UHFFFAOYSA-N 2-anilino-1,2-bis(furan-2-yl)ethanone Chemical compound C=1C=COC=1C(=O)C(C=1OC=CC=1)NC1=CC=CC=C1 ZOIWPXRLLGGGKK-UHFFFAOYSA-N 0.000 abstract 1
- OPVAMPWTRGMPIW-UHFFFAOYSA-N 3-chloro-n-[cyclopropyl-[5-(2-ethoxyethyl)thiophen-2-yl]methyl]-2-methylpyridin-4-amine Chemical compound S1C(CCOCC)=CC=C1C(C1CC1)NC1=CC=NC(C)=C1Cl OPVAMPWTRGMPIW-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- -1 N- (cyclopropyl-2-thienylmethyl) -3,4,5,7-tetrahydro-2-azocinamine Chemical compound 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 206010062519 Poor quality sleep Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 230000003474 anti-emetic effect Effects 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003589 local anesthetic agent Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- NIWZVGNHMJDRPS-UHFFFAOYSA-N n-[cyclopropyl(furan-2-yl)methyl]-4,5-dihydro-1,3-oxazol-2-amine Chemical compound C1CC1C(C=1OC=CC=1)NC1=NCCO1 NIWZVGNHMJDRPS-UHFFFAOYSA-N 0.000 abstract 1
- VHNMPXXNYLJDCV-UHFFFAOYSA-N n-[cyclopropyl(thiophen-2-yl)methyl]-2,3,4,5-tetrahydropyridin-6-amine Chemical compound C1CC1C(C=1SC=CC=1)NC1=NCCCC1 VHNMPXXNYLJDCV-UHFFFAOYSA-N 0.000 abstract 1
- SLGJPANGGWTZSK-UHFFFAOYSA-N n-[cyclopropyl(thiophen-2-yl)methyl]-3,4,5,6-tetrahydro-2h-azepin-2-amine Chemical compound C1CC1C(C=1SC=CC=1)NC1N=CCCCC1 SLGJPANGGWTZSK-UHFFFAOYSA-N 0.000 abstract 1
- VJHWETIJMQYHCX-UHFFFAOYSA-N n-[cyclopropyl(thiophen-2-yl)methyl]-4,5-dihydro-1,3-oxazol-2-amine Chemical compound C1CC1C(C=1SC=CC=1)NC1=NCCO1 VJHWETIJMQYHCX-UHFFFAOYSA-N 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de C-furano-2-il-metilamina y C-tiofeno-2-il-metilamina sustituidos, de la fórmula general (1), en la cual: A representa O ó S; R1 representa arilo, heterociclilo, -(alquil C1-6)-arilo o -(alquil C1-6)-heterociclilo; R2 representa -C(=O)R6 o cicloalquilo C3-8; R3, R4 y R5 representan independientemente entre sí H, F, Cl, Br, I, CN, OR7, SR8, NO2, alquilo C1-12, cicloalquilo C3-8, -(alquil C1-6)-cicloalquilo C3-8, arilo, -(alquil C1-6)-arilo, heterociclilo, -(alquil C1-6)-heterociclilo, -(CH2)m-O-(CH2)n-R9, siendo m = 1, 2, 3 ó 4 y n = 0, 1, 2, 3 ó 4, -(CH2)p-Sq-(CH2)r-R10, siendo p = 1, 2, 3 ó 4, q = 1 ó 2 y r = 0, 1, 2, 3 ó 4, -(CH2)s-C(=O)OR11 siendo s = 0, 1, 2, 3 ó 4, -C(=O)R12 o C(=S)R13; R6 representa arilo, heterociclilo, -(alquil C1-6)-arilo o -(alquil C1-6)-heterociclilo; R7 y R8 representan independientemente entre sí H, alquilo C1-6 o cicloalquilo C3-8; R9 y R10 representan independientemente entre sí H, alquilo C1-6, cicloalquilo C3-8, arilo, heterociclilo o -C(=O)R14; R11 representa H, alquilo C1-6 o cicloalquilo C3-8; R12 y R13 representan independientemente entre sí alquilo C1-6, cicloalquilo C3-8, -(alquil C1-6)-cicloalquilo C3-8, arilo, -(alquil C1-6)-arilo, heterociclilo, -(alquil C1-6)-heterociclilo o -NR15R16; R14 representa independientemente de los demás sustituyentes alquilo C1-6, cicloalquilo C3-8, -(alquil C1-6)-cicloalquilo C3-8, arilo o -(alquil C1-6)-arilo; y R15 y R16 representan independientemente entre sí H, alquilo C1-8, cicloalquilo C1-8, -(alquil C1-6)-cicloalquilo C3-8, arilo, -(alquil C1-6)-arilo, heterociclilo o -(alquil C1-6)-heterociclilo; o -NR15R16 forman un anillo de heterociclilo; en forma de sus racematos, en forma de sus enantiómeros o diastereómeros puros o en forma de mezclas de los enantiómeros y diastereómeros en cualquier proporción; con excepción de N-(ciclopropil-2-tienilmetil)-4,5-dihidro-2-oxazolamina; N-(ciclopropil-2-furanilmetil)-4,5-dihidro-2-oxazolamina; 1,2-di-2-furanil-2-(fenilamino)-etanona; 1,2-di-2-furanil-2-(pirazinilamino)-etanona; 5-cloro-N-[ciclopropil[5(2-etoxietil)-2-tienil]metil]-6-metil-4-piridinamina; N-(ciclopropil-2-tienilmetil)-3,4,5,6-tetrahidro-2-piridinamina; N-(ciclopropil-2-tienilmetil)-3,4,5,6-tetrahidro-2H-azepinamina; y N-(ciclopropil-2-tienilmetil)-3,4,5,7-tetrahidro-2-azocinamina; procedimiento para su preparación, y medicamentos y composiciones farmacéuticas de efecto analgésico, anestésico local, antiarrítmico, antiemético, nootrópico y/o un medicamento para el tratamiento y/o profilaxis de enfermedades cardiovasculares, incontinencia urinaria, diarrea, prurito y/o inflamaciones y/o un medicamento para el tratamiento de depresiones y/o abuso de alcohol y/o drogas y/o medicamentos y/o un medicamento para el incremento de la vigilia, que los contienen. Preparación de un compuesto de fórmula (1) en la que una amina de la fórmula general R1-NH2 en la cual R1 tiene el significado arriba definido, se hace reaccionar con un compuesto de la fórmula general R2-C(O)H, en la que R2 tiene el significado arriba definido, y un heterociclo de la fórmula general (2), en la cual A, R3, R4 y R5 tienen los significados arriba definidos, en presencia de un ácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10125145A DE10125145A1 (de) | 2001-05-22 | 2001-05-22 | Substituierte C-Furan-2-yl-methylamin- und C-Thiophen-2-yl-methylamin-Derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035982A1 true AR035982A1 (es) | 2004-07-28 |
Family
ID=7685874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101843A AR035982A1 (es) | 2001-05-22 | 2002-05-17 | Derivados de c-furano-2-il-metilamina y c-tiofeno-2-il-metilamina sustituidos y metodo de preparacion |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6878740B2 (es) |
| EP (1) | EP1392670B1 (es) |
| JP (1) | JP2004532246A (es) |
| AR (1) | AR035982A1 (es) |
| AT (1) | ATE299873T1 (es) |
| AU (1) | AU2002338989B2 (es) |
| CA (1) | CA2448038C (es) |
| DE (2) | DE10125145A1 (es) |
| DK (1) | DK1392670T3 (es) |
| ES (1) | ES2242869T3 (es) |
| HU (1) | HUP0401162A3 (es) |
| MX (1) | MXPA03010601A (es) |
| PE (1) | PE20021099A1 (es) |
| PL (1) | PL367535A1 (es) |
| PT (1) | PT1392670E (es) |
| SI (1) | SI1392670T1 (es) |
| WO (1) | WO2002094802A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| KR100553398B1 (ko) * | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체 |
| AU2010270797B2 (en) | 2009-07-08 | 2015-03-19 | Dermira (Canada), Inc. | TOFA analogs useful in treating dermatological disorders or conditions |
| WO2015077574A1 (en) * | 2013-11-22 | 2015-05-28 | Teva Branded Pharmaceutical Products R&D, Inc. | An inhalable medicament |
| CN109153659A (zh) * | 2016-05-31 | 2019-01-04 | 翰林大学产学研合作团队 | 五元杂环衍生物、其制备方法及包含其的药剂学组合物 |
| CN112521357B (zh) * | 2020-08-31 | 2021-10-08 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3816457A (en) * | 1973-01-05 | 1974-06-11 | Richardson Merrell Inc | Lactamimide derivatives |
| US3890445A (en) * | 1973-01-05 | 1975-06-17 | Richardson Merrell Inc | Lactamimide derivatives useful as hypoglycemic agents |
| WO2001068816A1 (en) | 2000-03-13 | 2001-09-20 | Smithkline Beecham Corporation | Human histamine h3 gene variant-3 |
| DE10012820A1 (de) * | 2000-03-16 | 2001-09-20 | Bayer Ag | Substituierte 1-Aryl-cyclopropylmethylamino-1,3,5-triazine |
| DE10059864A1 (de) * | 2000-11-30 | 2002-06-13 | Gruenenthal Gmbh | Substituierte Amino-furan-2-yl-essigsäure- und Amino-thien-2-yl-essigsäure-Derivate |
-
2001
- 2001-05-22 DE DE10125145A patent/DE10125145A1/de not_active Withdrawn
-
2002
- 2002-05-17 AR ARP020101843A patent/AR035982A1/es not_active Application Discontinuation
- 2002-05-21 SI SI200230178T patent/SI1392670T1/sl unknown
- 2002-05-21 CA CA2448038A patent/CA2448038C/en not_active Expired - Fee Related
- 2002-05-21 DE DE50203686T patent/DE50203686D1/de not_active Expired - Lifetime
- 2002-05-21 PL PL02367535A patent/PL367535A1/xx not_active Application Discontinuation
- 2002-05-21 PT PT02743057T patent/PT1392670E/pt unknown
- 2002-05-21 HU HU0401162A patent/HUP0401162A3/hu unknown
- 2002-05-21 PE PE2002000428A patent/PE20021099A1/es not_active Application Discontinuation
- 2002-05-21 EP EP02743057A patent/EP1392670B1/de not_active Expired - Lifetime
- 2002-05-21 WO PCT/EP2002/005542 patent/WO2002094802A1/de not_active Ceased
- 2002-05-21 AT AT02743057T patent/ATE299873T1/de not_active IP Right Cessation
- 2002-05-21 ES ES02743057T patent/ES2242869T3/es not_active Expired - Lifetime
- 2002-05-21 MX MXPA03010601A patent/MXPA03010601A/es active IP Right Grant
- 2002-05-21 DK DK02743057T patent/DK1392670T3/da active
- 2002-05-21 AU AU2002338989A patent/AU2002338989B2/en not_active Ceased
- 2002-05-21 JP JP2002591475A patent/JP2004532246A/ja active Pending
-
2003
- 2003-11-21 US US10/717,932 patent/US6878740B2/en not_active Expired - Fee Related
-
2005
- 2005-03-07 US US11/072,962 patent/US7317034B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002094802A1 (de) | 2002-11-28 |
| HUP0401162A3 (en) | 2007-05-02 |
| US20050148550A1 (en) | 2005-07-07 |
| CA2448038C (en) | 2010-09-28 |
| JP2004532246A (ja) | 2004-10-21 |
| ATE299873T1 (de) | 2005-08-15 |
| SI1392670T1 (sl) | 2005-12-31 |
| US7317034B2 (en) | 2008-01-08 |
| US6878740B2 (en) | 2005-04-12 |
| EP1392670B1 (de) | 2005-07-20 |
| EP1392670A1 (de) | 2004-03-03 |
| DK1392670T3 (da) | 2005-08-08 |
| HUP0401162A2 (hu) | 2004-10-28 |
| CA2448038A1 (en) | 2002-11-28 |
| MXPA03010601A (es) | 2004-03-09 |
| DE50203686D1 (en) | 2005-08-25 |
| AU2002338989B2 (en) | 2007-06-07 |
| PL367535A1 (en) | 2005-02-21 |
| PT1392670E (pt) | 2005-10-31 |
| DE10125145A1 (de) | 2002-11-28 |
| PE20021099A1 (es) | 2003-01-25 |
| US20040152734A1 (en) | 2004-08-05 |
| ES2242869T3 (es) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090577T8 (en) | Use of crth2 antagonist compounds in therapy | |
| AR041672A1 (es) | Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo | |
| SE0201937D0 (sv) | Therapeutic agents | |
| DE60218048D1 (de) | Thiophenverbindungen als arzneimittel | |
| ATE163012T1 (de) | N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
| SE9702799D0 (sv) | New compounds | |
| HRP20110498T1 (hr) | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti | |
| EA200600527A1 (ru) | Активирующее ppar соединение и содержащая его фармацевтическая композиция | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| SE9703377D0 (sv) | New compounds | |
| SE0101579D0 (sv) | New compounds | |
| AR035982A1 (es) | Derivados de c-furano-2-il-metilamina y c-tiofeno-2-il-metilamina sustituidos y metodo de preparacion | |
| JP2005515976A5 (es) | ||
| SE9703378D0 (sv) | New compounds | |
| ATE54913T1 (de) | Industrielle verbindungen anwendbar als zwischenprodukte in der herstellung von in stellung 2 substituierten 4-hydroxy 3quinolincarboxamid-derivaten und die herstellung von diesen zwischenprodukten. | |
| IL150126A0 (en) | Novel 4(piperazinyl(8-quinolinyl)methyl) benzamides | |
| PE20020426A1 (es) | ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN | |
| DE69512208D1 (de) | Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren | |
| ATE211137T1 (de) | Substituierte benzylthienylpiperazine, ihre anwendung als arzneimittel und verfahren für ihre herstellung | |
| DE69910083D1 (de) | Katecholhydrazon-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten | |
| CA2373395A1 (en) | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | |
| DK381188A (da) | 2-amino-5-hydroxy-4-pyrimidon-forbindelser og deres anvendelse til fremstilling af et laegemiddel til behandling af inflammation eller andre leukotrien-formidlede sygdomme samt farmaceutiske praeparater indeholdende forbindelserne | |
| HRP20060023A2 (en) | Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |